References
- Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes. In:. Diabetes in America 2nd edn. National Diabetes Information Clearinghouse, Bethesda, MD, 47–68, Available at: http://diabetes.niddk.nih.gov/dm/pubs/america/contents.htm[accessed 11 October 2007]
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). National Diabetes Statistics. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm [accessed 11 October 2007].
- National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Fact Sheet. Available at: http://www.cdc.gov/diabetes/pubs/factsheet05.htm [accessed 11 October 2007].
- Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion 2004; 20((Suppl 1))S5–S26
- Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. Journal of Clinical Endocrinology and Metabolism 1994; 78: 809A–809F
- American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care 2007; 30((Suppl 1))S4–S41
- Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Archives of Internal Medicine 2003; 163: 1306–1316
- American Diabetes Association. Available at: http://www.diabetes.org/home.jsp[accessed 11 October 2007].
- Byetta® [prescribing information]. Amylin Pharmaceuticals, 2007. Available at: http://pi.lilly.com/us/byetta-pi.pdf[accessed 11 October 2007].
- Buse JB, Henry RB, Han J, et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628–2635.
- Defronzo RA, Ratner RE, Han J, et al. Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092–1100.
- Kendall DM, Riddle MC, Rosenstock J. Effects of exenatide on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083–1091
- Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman & Hall, London, UK 1993
- Managed Care Dossier. BYETTA® (exenatide). Eli Lilly, Indianapolis, IN 2005
- Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. Oxford University Press, Oxford, UK 1996
- Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27: 1218–1224
- Siminerio L. Challenges and strategies for moving patients to injectable medications. The Diabetes Educator 2006; 32((Suppl 2))S82–S90
- Secnik Boye K, Matza LS, Oglesby A, et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health and Quality of Life Outcomes 2006; 4: 80